News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Related Content
Trending on PharmExec
1
Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results
2
Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg
3
Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson
4
Novavax's Strategy Across Commercial, R&D, and Partnerships
5